Travere CMO gifts 468 shares to charity fund

Travere Therapeutics, Inc. chief medical officer Jula Inrig reported a bona fide gift of 468 shares of common stock to a donor-advised fund.

Accepted by SEC EDGAR 06/22/2026 - 04:37 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Travere Therapeutics, Inc. chief medical officer Jula Inrig reported a bona fide gift of 468 shares of common stock to a donor-advised fund. The gift was authorized on June 16, 2026, and transferred on June 22, 2026, at a reported price of $0.00 per share. Following this charitable transfer, Inrig directly holds 112,770 shares of Travere Therapeutics common stock, indicating this was a relatively small, non-market transaction within her overall position.

Insider Trade Summary

468 shares gifted

Gift 1 txn

Insider Inrig Jula

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Gift	Common Stock	468	$0.00	$0.00

Holdings After Transaction: Common Stock — 112,770 shares (Direct)

Holdings Before and After: Common Stock, 113,238 to 112,770 shares (Direct)

Footnotes (1)

1. F1. This transaction represents a bona fide gift of 468 shares of common stock to a donor-advised fund. The reporting person authorized the gift on June 16, 2026, and the transfer occurred on June 22, 2026.

Key Figures

Shares gifted: 468 shares Reported gift price: $0.00 per share Shares held after transaction: 112,770 shares +1 more

4 metrics

Shares gifted 468 shares Bona fide gift of Travere common stock

Reported gift price $0.00 per share Gift of 468 shares to donor-advised fund

Shares held after transaction 112,770 shares Direct holdings following June 22, 2026 gift

Gift transaction count 1 transaction Form 4 transactionSummary giftCount

Key Terms

bona fide gift, donor-advised fund, Common Stock

3 terms

bona fide gift financial

"This transaction represents a bona fide gift of 468 shares of common stock"

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

donor-advised fund financial

"gift of 468 shares of common stock to a donor-advised fund"

A donor-advised fund is a charitable giving account that lets an individual or family deposit cash, stock, or other assets now, get an immediate tax benefit, and then recommend grants to charities over time. Think of it like a private charitable bucket you control without running a charity yourself; investors care because it’s a tax-efficient way to give appreciated securities, can change when and how donated shares enter the market, and affects personal and corporate tax planning.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Travere Therapeutics (TVTX) report for Jula Inrig?

Travere’s chief medical officer Jula Inrig reported a bona fide gift of 468 common shares. The shares were donated to a donor-advised fund, reflecting a charitable transfer rather than a market trade involving a purchase or sale of Travere stock.

Was the Travere Therapeutics (TVTX) Jula Inrig transaction a stock sale?

No, the transaction was not a sale. Jula Inrig made a bona fide gift of 468 Travere common shares to a donor-advised fund, reported at a price of $0.00 per share, meaning no cash proceeds were received from this transfer.

How many Travere Therapeutics (TVTX) shares did Jula Inrig hold after the reported gift?

After gifting 468 shares, Jula Inrig directly held 112,770 shares of Travere Therapeutics common stock. This shows the charitable transfer represented only a small portion of her overall reported holdings in the company’s equity.

When did Jula Inrig’s Travere Therapeutics (TVTX) stock gift occur?

Jula Inrig authorized the gift on June 16, 2026, and the transfer of 468 Travere Therapeutics common shares to a donor-advised fund occurred on June 22, 2026, as reflected in the Form 4 insider transaction disclosure.

What does a bona fide gift mean in the Travere Therapeutics (TVTX) Form 4?

A bona fide gift in this context means shares were transferred without payment as a genuine charitable contribution. For Travere Therapeutics, Jula Inrig donated 468 common shares to a donor-advised fund, reflecting a non-market disposition rather than an investment-driven trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Inrig Jula

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/22/2026		G(1)		468	D	$0	112,770	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction represents a bona fide gift of 468 shares of common stock to a donor-advised fund. The reporting person authorized the gift on June 16, 2026, and the transfer occurred on June 22, 2026.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)